Nyxoah Reports Third Quarter 2026 Financial and Operating Results
Globe Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Global Q3 net revenue €9.2 million, up 19% sequentially
- ➤U.S. Q3 net revenue €6.7 million, up 29% sequentially
- ➤2026 revenue guidance €33 million to €35 million
- ➤FDA PMA supplement submitted to expand Genio indication to CCC patients
- ➤ACCCESS study delivered 77.2% 12-month AHI responder rate, with zero serious adverse events
Expert Statements
Liam Kelly, Chief Executive Officer of Nyxoah
“We delivered 29% sequential U.S. revenue growth in the third quarter, an acceleration from 22% in the second quarter.”
Liam Kelly, Chief Executive Officer of Nyxoah
“Momentum is building as physicians and centers gain experience with Genio.”
Liam Kelly, Chief Executive Officer of Nyxoah
“We see this reflected in the growing base of trained surgeons and active accounts in the U.S., and in the positive physician and patient feedback we receive on the Genio system.”
Liam Kelly, Chief Executive Officer of Nyxoah
“Our ACCCESS results and our PMA supplement submission could extend Genio to complete concentric collapse patients in the U.S., who have limited treatment options today.”
Liam Kelly, Chief Executive Officer of Nyxoah
“We remain confident in our ability to build durable growth in the U.S. and to improve care for OSA patients.”
Nyxoah Reports Third Quarter 2026 Financial and Operating Results
Global net revenue was €9.2 million driven by 29% sequential U.S. net revenue growth PMA supplement submitted to the FDA to expand Genio’s U.S. indication to include Complete Concentric Collapse patients
Get started
Create a free account to read the full story.